about
The type 1 TNF receptor and its associated adapter protein, FAN, are required for TNFalpha-induced sickness behavior.Impaired adrenocorticotropic hormone response to bacterial endotoxin in mice deficient in prostaglandin E receptor EP1 and EP3 subtypesAge-dependent changes in 24-hour rhythms of catecholamine content and turnover in hypothalamus, corpus striatum and pituitary gland of rats injected with Freund's adjuvantRethinking inflammation: neural circuits in the regulation of immunity.Alcoholism and inflammation: neuroimmunology of behavioral and mood disordersAssociation of Baseline Sleep Quality With Trajectories of Depressive Symptoms in Patients Undergoing Interferon TreatmentImmune-Challenged Fish Up-Regulate Their Metabolic Scope to Support LocomotionElevation in type I interferons inhibits HCN1 and slows cortical neuronal oscillationsWhy Do We Feel Sick When Infected--Can Altruism Play a Role?Infection-induced proinflammatory cytokines are associated with decreases in positive affect, but not increases in negative affect.Inhibition of vagally mediated immune-to-brain signaling by vanadyl sulfate speeds recovery from sickness.Prostaglandin E receptor EP1 controls impulsive behavior under stress.Early-life programming of later-life brain and behavior: a critical role for the immune system.Neuropsychiatric symptoms in patients with aortic aneurysms.Activation of lung toll-like receptors does not exacerbate sickness responses to lipopolysaccharide in mice.A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkersThe olfactory nerve has a role in the body temperature and brain cytokine responses to influenza virus.Implications of immune-to-brain communication for sickness and painImmune system-central nervous system interactions: effect and immunomodulatory consequences of immune system mediators on the brain.Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancerDysthymia: a review of pharmacological and behavioral factors.Different receptor mechanisms mediate the pyrogenic and behavioral effects of interleukin 1.In vitro and in vivo evidence for a role of the P2X7 receptor in the release of IL-1 beta in the murine brainDifference by sex but not by race/ethnicity in the visceral adipose tissue-depressive symptoms association: the Multi-Ethnic Study of Atherosclerosis.Neuropsychiatric adverse effects of interferon-alpha: recognition and management.Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions.Understanding cytokines. Part I: Physiology and mechanism of action.Neuropathic pain-induced depressive-like behavior and hippocampal neurogenesis and plasticity are dependent on TNFR1 signalingRole of circumventricular organs in pro-inflammatory cytokine-induced activation of the hypothalamic-pituitary-adrenal axis.Anterior cingulate activation and error processing during interferon-alpha treatmentNeonatal stress modulates sickness behavior.Depression, cytokines, and pancreatic cancerImmunoglobulin-mediated neuro-cognitive impairment: new data and a comprehensive review.Perturbation of chemokine networks by gene deletion alters the reinforcing actions of ethanolSex differences in the response to influenza virus infection: modulation by stressA biological pathway linking inflammation and depression: activation of indoleamine 2,3-dioxygenase.Fatigue in cholestatic liver disease--a perplexing symptomImmune system to brain signaling: neuropsychopharmacological implications.Behavioral and motivational effects of immune-system activation.LPS exposure increases maternal corticosterone levels, causes placental injury and increases IL-1Β levels in adult rat offspring: relevance to autism.
P2860
Q24648146-069760AB-B7E8-415A-B21A-B4C651B61287Q24683277-11E39EAF-AA10-4A89-8D44-FF22AC7816ABQ24796836-DD60E5DB-9845-4B3D-A1CE-CDB19484B187Q26998822-DDB66827-F8E6-42BD-8451-E616BD09FD8AQ28302013-387DE8B3-C66C-4948-AAA9-1C1D5ABB8904Q28387292-2E4B8B7F-1990-452E-9E16-B561564E1814Q28553564-A1977B8A-C005-418A-9ECA-4559EA37156CQ28568408-6799D003-A103-47C6-9F36-4DEAC744408FQ28611054-36A2479D-A444-4C6C-833F-845AAE96A2B6Q30439385-8BC00964-47AD-4AFA-9A13-0A8EE6FEDDADQ30476283-597505BA-AC1A-4F4F-9FEA-710E04892A54Q30476333-47579213-F68E-4BDC-9F79-9BD1F4540387Q30487006-F7983711-2EAE-46B0-A744-F141C29C298EQ31028708-F07F13EC-5F73-4D62-A10B-F4CBA1660940Q33553907-6AC280B1-8331-4A9F-BE24-C29C35AFF7E0Q33587452-F72EE6C1-1210-4B1A-891C-C6519A3D46D5Q33637790-52CDFF6A-04DB-435A-AB42-106664ED7F4CQ33679530-EB76CD8E-E8FA-4772-A334-40CC15742CF1Q33746873-9A459F06-6710-4D1F-99F2-7AFF802F967EQ33910359-846545FC-E474-48BD-A8BB-EB9DB1EBE1D5Q33964349-E0985D2C-7280-4A1B-98DC-2181E6D50024Q33971359-28A9A441-9598-4F3E-AF9B-30B9CEF82A8CQ34011838-4798D56B-9BED-4790-9AB9-193D499CED2FQ34053569-3E05725B-FBCC-4217-8228-37B8B7162893Q34081783-EC69D3AD-F0C7-43E8-90A0-8FE2CCD4FBB5Q34137763-EF67E23C-213B-4102-B7A2-116AC4036B47Q34171362-232D0DC7-9405-4FC5-A1FE-0590BC755F95Q34203214-E30B59FB-A678-4CDA-BDA3-F37D9B67E83AQ34311135-DCAAC397-4D7F-4327-B6C6-F68C233FCCF2Q34350258-1458AF3D-7154-4F6C-817F-D2D133F02BD3Q34441102-461680E2-11F1-4D1C-A41B-338AEFEC479AQ34453593-49CDA577-D45D-460F-A61F-7ED06F7A8FDDQ34550430-F4D0AFF0-14B5-43CE-B6FA-60B86C6D0B41Q34578591-7F9DCDD6-30F4-4302-B24B-5A5CFF861BADQ34579360-E0B0C738-1EB6-43A9-8776-4FCE7E7E20BEQ34631232-593A1B7C-D317-4A38-A616-2D586B422142Q34769039-CD06F1C5-93AE-4777-9607-952F2C19A4EDQ34769827-495B3E56-EA07-4FA2-95BB-5214A0097588Q35031612-AA95C6A1-B527-4D28-97DA-49FD0C6828C5Q35061499-344B5915-3632-4CB4-850E-F110A762FF58
P2860
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Sickness behavior as a new target for drug development.
@ast
Sickness behavior as a new target for drug development.
@en
type
label
Sickness behavior as a new target for drug development.
@ast
Sickness behavior as a new target for drug development.
@en
prefLabel
Sickness behavior as a new target for drug development.
@ast
Sickness behavior as a new target for drug development.
@en
P2093
P1476
Sickness behavior as a new target for drug development.
@en
P2093
P356
10.1016/0165-6147(92)90012-U
P577
1992-01-01T00:00:00Z